Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-20
2005-09-20
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S343000, C514S359000, C514S365000, C514S423000, C514S424000, C544S372000, C546S278400, C548S200000, C548S260000, C548S531000, C548S556000
Reexamination Certificate
active
06946468
ABSTRACT:
The present invention relates to inhibitors of ras farnesylation of the Formula Iwherein:R1is for example H and further values as defined in the specification; R2is for example H and further values as defined in the specification; R3is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3values can be the same or different; L is a linking moiety for example —CH2—NH— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing upto 5 heteroatoms where the heteroatoms are independently selected from O, N & S; or a —S—S— dimer thereof when R2═H; or a N-oxide or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation their use as therapeutic agents and pharmaceutical compositions containing them.
REFERENCES:
patent: 5185248 (1993-02-01), Barbacid et al.
patent: 5929077 (1999-07-01), Leftheris
patent: 6541491 (2003-04-01), Davies et al.
patent: 0 126 587 (1984-11-01), None
patent: 0 182 213 (1986-05-01), None
patent: 0 272 456 (1988-06-01), None
patent: 0 280 771 (1988-09-01), None
patent: 0 442 497 (1991-08-01), None
patent: 0 443 883 (1991-08-01), None
patent: 0 508 682 (1992-10-01), None
patent: 0 518 558 (1992-12-01), None
patent: 0 521 524 (1993-01-01), None
patent: 0 537 007 (1993-04-01), None
patent: 0 560 613 (1993-09-01), None
patent: 0 562 855 (1993-09-01), None
patent: 0 581 500 (1994-02-01), None
patent: 0 581 501 (1994-02-01), None
patent: 0 581 502 (1994-02-01), None
patent: 0 590 885 (1994-04-01), None
patent: 0 592 167 (1994-04-01), None
patent: 0 618 221 (1994-10-01), None
patent: 0 696 593 (1996-02-01), None
patent: 60233076 (1985-11-01), None
patent: 03115285 (1991-05-01), None
patent: 04368386 (1992-12-01), None
patent: 05078360 (1993-03-01), None
patent: 05239058 (1993-09-01), None
patent: WO 92/17479 (1992-10-01), None
patent: WO 92/17480 (1992-10-01), None
patent: WO 93/15078 (1993-08-01), None
patent: WO 93/19070 (1993-09-01), None
patent: WO 93/21186 (1993-10-01), None
patent: WO 94/04561 (1994-03-01), None
patent: WO 95/00497 (1995-01-01), None
patent: WO 95/09000 (1995-04-01), None
patent: WO 95/09001 (1995-04-01), None
patent: WO 95/25086 (1995-09-01), None
patent: WO 96/09821 (1996-04-01), None
patent: WO 97/05135 (1997-02-01), None
patent: 97/06138 (1997-02-01), None
Ayral-Kaloustian et al., Ras Farnesyltransferase Inhibitors, Annual Reports in Medicinal Chemistry, vol. 31, pp. 171-180, 1996.
Evans, B., et al., “Nanomolar-Affinity, Non-Peptide Oxytocin Receptor Antagonists,”J. Med. Chem.36(25):3993-4005 (1993).
Garcia, Ana M., et al., “Peptidomimetic Inhibitors of Ras Farnesylation and Function in Whole Cells,”J. Biol. Chem.268:18415-18418 (1993).
Graham, Samuel L., et al., “Pseudopeptide Inhibitors of Ras Farnesyl-Protein Transferase,”J. Med. Chem.37:725-730 (1994).
Kemp, D.S., et al., “Studies of N-Terminal Templates for α-Helix Formation: Synthesis and Conformational Analysis of (2S,5S,8S,11S)-1-Acetyl-1,4-diaza-3-keto-5-carboxy-10-thiatricyclo[2.8.104.8]-tridecane (Ac-Hel1-OH),”J. Org. Chem.56:6672-6682 (1991).
Kohl, Nancy E., et al., “Selective Inhibition of ras-Dependent Transformation by a Farnesyl-transferase Inhibitor,”SCIENCE260:1934-1937 (1993).
Lern, Edwina C., et al., “Ras CAAX Peptidomimetic FTI-277 Selectivity Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes,”J. of Biol. Chem.270:26802-26806 (1995).
Magolda, R.L.., et al., “Design and Synthesis of Conformationally Restricted Phospholids as Phospholipase A2 Inhibitors,”J. Cellular Biochemistry40:371-386 (1989).
Matsumura, H., et al., “An Efficient Synthesis of (2S,4S)-2-Substituted 4-Mercaptopyrrolidine Derivatives,”Heterocycles41:No. 1, 147-159 (1995).
Sunagawa, M., et al., “A Novel Carbapenem Antibiotic, SM-7338 Structure-Activity Relationships,”J. Antibioticsvol. XLIII No. 5, pp. 519-532 (1990).
Sunagawa, M., et al., “Synthesis and Antibacterial Activity of Novel Carbapenems with a Catechol or Hydroxypyridone Moiety,”J. Antibiotics47(11):1354-1358 (1994).
Boyle Francis Thomas
Wardleworth James Michael
Coleman Brenda
Morgan & Lewis & Bockius, LLP
Zeneca Limited
LandOfFree
3-mercaptopyrrolidines as farnesyl protein transferase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-mercaptopyrrolidines as farnesyl protein transferase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-mercaptopyrrolidines as farnesyl protein transferase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3382661